Subscribe To

Price Alert Latest News Economic Calendar News

MOR / MorphoSys shares gain as endometrial cancer treatment gets fast-track designation

MorphoSys AG's American depositary receipts MOR, +1.38% gained 2% premarket on Wednesday after the biopharma company said its investigational treatment for endometrial cancer was granted fast-track designation by the U.S. Food and Drug Administration. The treatment, tulmimetostat, is designed for patients with advanced, recurrent or metastatic endometrial cancer who have progressed on at least one prior line of treatment. Read More

Demo Live Account See Partner Details

Content Topics

Morphosys

Gain

Endometrial

Cancer

Treatment

Gets

Fast track

Designation

Stock

MOR

Posted: Sep 13 2023, 08:11

Author Name: Market Watch

MOR News

By Market Watch
September 13, 2023

MorphoSys shares gain as endometrial cancer treatment gets fast-track designation

MorphoSys AG's American depositary receipts MOR, +1.38% gained 2% premarket on Wednesday after the biopharma company said its investigational treatmen

By Seeking Alpha
May 6, 2023

MorphoSys AG (MOR) Q1 2023 Earnings Call Transcript

MorphoSys AG (NASDAQ:MOR ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Inv

By Accesswire
April 27, 2023

Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarte

By Zacks Investment Research
April 6, 2023

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this

By The Motley Fool
April 5, 2023

Why Shares of MorphoSys Are Up Wednesday

MorphoSys had said it planned to cut preclinical programs and trim its workforce. The company said it expected top-line results for a myelofibrosis dr

By Accesswire
March 9, 2023

Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the f

By Seeking Alpha
February 1, 2023

MorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term Catalyst

MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's tw

By Seeking Alpha
January 6, 2023

MorphoSys AG: Staying On The Sidelines

MorphoSys caps off a year of bad news with the departure of its CFO. With gantenerumab done for now, the key P&L driver will be Monjuvi, a product tha

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.